193 related articles for article (PubMed ID: 16572409)
1. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.
Lamerato L; Havstad S; Gandhi S; Jones D; Nathanson D
Cancer; 2006 May; 106(9):1875-82. PubMed ID: 16572409
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
3. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia.
Groot MT; Baltussen R; Uyl-de Groot CA; Anderson BO; Hortobágyi GN
Breast J; 2006; 12 Suppl 1():S81-90. PubMed ID: 16430401
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
6. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Sasser AC; Rousculp MD; Birnbaum HG; Oster EF; Lufkin E; Mallet D
Womens Health Issues; 2005; 15(3):97-108. PubMed ID: 15894195
[TBL] [Abstract][Full Text] [Related]
8. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
[TBL] [Abstract][Full Text] [Related]
9. [Advanced breast cancer: an evaluation of the cost of recurrence].
Bercez C; Lebrun T; Bonneterre ME; Selke B; Lenne X; Bonneterre J
Bull Cancer; 1999 Jun; 86(6):585-90. PubMed ID: 10417432
[TBL] [Abstract][Full Text] [Related]
10. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients.
Trinh XB; Tjalma WA; Makar AP; Buytaert G; Weyler J; van Dam PA
Fertil Steril; 2008 Jul; 90(1):17-22. PubMed ID: 17706209
[TBL] [Abstract][Full Text] [Related]
11. Clinical model of lifetime cost of treating bladder cancer and associated complications.
Avritscher EB; Cooksley CD; Grossman HB; Sabichi AL; Hamblin L; Dinney CP; Elting LS
Urology; 2006 Sep; 68(3):549-53. PubMed ID: 16979735
[TBL] [Abstract][Full Text] [Related]
12. The role of reexcision for positive margins in optimizing local disease control after breast-conserving surgery for cancer.
Aziz D; Rawlinson E; Narod SA; Sun P; Lickley HL; McCready DR; Holloway CM
Breast J; 2006; 12(4):331-7. PubMed ID: 16848842
[TBL] [Abstract][Full Text] [Related]
13. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
14. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
[TBL] [Abstract][Full Text] [Related]
15. Association between operative closure type and acute infection, local recurrence, and disease surveillance in patients undergoing breast conserving therapy for early-stage breast cancer.
Indelicato D; Grobmyer SR; Newlin H; Morris CG; Haigh LS; Copeland EM; Mendenhall NP
Surgery; 2007 May; 141(5):645-53. PubMed ID: 17462465
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
17. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
[TBL] [Abstract][Full Text] [Related]
18. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of breast cancer in California.
Max W; Sung HY; Stark B
Breast Cancer Res Treat; 2009 Jul; 116(1):201-7. PubMed ID: 18683041
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]